Medipharm Labs Corp. is a Canadian contract development and manufacturing organization (CDMO) specializing in pharmaceutical-grade cannabis formulations. The company partners with licensed producers and brand owners to deliver science-based product development, formulation and manufacturing services across a variety of dosage forms.
Its capabilities include the design and production of oils, capsules, tablets, soft gels, topical creams and vape cartridges, leveraging proprietary formulation technologies such as nanoemulsions and controlled-release systems. Medipharm Labs operates a fully integrated, Good Manufacturing Practice (GMP) certified facility, offering analytical testing, stability studies and scale-up support from pilot to commercial volumes.
Headquartered in Laval, Quebec, Medipharm Labs serves clients in Canada and select international markets where cannabis derivatives are permitted. The company’s facility infrastructure and analytical laboratories enable compliance with regulatory requirements in multiple jurisdictions, supporting both medical and adult-use applications.
Founded in the mid-2010s, Medipharm Labs has built a portfolio of patented cannabis formulation technologies and matured its service offering under the leadership of Chief Executive Officer David Stewart. The management team draws on pharmaceutical industry experience to drive innovation in cannabinoid product development and to scale manufacturing operations in response to evolving market demand.
AI Generated. May Contain Errors.